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Abstract
During recent years, the high phospholipase A2 (PLA2) concentrations at sites of inflammation and in circulation in
several life-threatening diseases, such as sepsis, multi-organ dysfunction and acute respiratory distress syndrome, has
generally been ascribed to the non-pancreatic group IIA PLA2. Recently the family of secreted low molecular mass PLA2
enzymes has rapidly expanded. In some cases, a newly described enzyme appeared to be cross-reactive with antibodies
against the group IIA enzyme. For this reason, reports describing the expression of group IIA PLA2 during inflammatory
conditions need to be reevaluated. Here we describe the identification of the PLA2 activity in sera of acute chest syndrome
patients and in sera of trauma victims. In both cases, the PLA2 activity was identified as group IIA. This classification was
based upon cross-reactivity with monoclonal antibodies against group IIA PLA2 which do not recognize the recombinant
human group V enzyme. Moreover, purification of the enzymatic activity from the two sera followed by N-terminal amino
acid sequence analyses revealed only the presence of group IIA enzyme. ß 2000 Elsevier Science B.V. All rights reserved.
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1. Introduction
Phospholipase A2 (PLA2 ; phosphatide 2-acyl hy-
drolase, EC 3.1.1.4) speci¢cally hydrolyzes the fatty
acyl ester bonds at the sn-2 position of sn-3 phospho-
glycerides, producing free fatty acids, including ara-
chidonic acid and lysophospholipids (for reviews see
[1,2]). These products are the rate-limiting precursors
in the biosynthesis of a variety of bioactive lipids,
including prostaglandins, hydroxy fatty acids, leuko-
trienes, prostacyclins, thromboxane and platelet-acti-
vating factor [3^5]. Phospholipase A2 can be subdi-
vided into several groups based upon their molecular
mass, Ca2-dependence, molecular structure, local-
ization of disul¢de bridges, and their intracellular
and/or extracellular localization [6^8].
The most extensively studied of the mammalian
low molecular mass PLA2s are the group IB PLA2s,
present in pancreatic tissue and pancreatic juice [9]
and group IIA PLA2s, present in many cell types [2].
The latter enzyme has also been reported to be
present extracellularly in high concentrations in
synovial £uid and plasma of individuals su¡ering
from rheumatoid arthritis [10^13] and in plasma of
patients with diseases, such as sepsis [14^15], malaria
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[16] and acute chest syndrome [17]. In many of these
studies, the PLA2 levels re£ect the severity of the
pathological conditions [11^13,15,17].
The last couple of years the family of mammalian
low molecular mass PLA2 enzymes has been ex-
tended considerably [8], with the discovery of the
Ca2-dependent secretory PLA2s groups IIC, IID,
IIE, IIF, V and X. Group IIC enzyme is mainly ex-
pressed in testes and has been cloned from rat and
mouse [18,19]. In man however, it appears to be a
non-functional pseudogene [20]. The IID secretory
phospholipase A2 (sPLA2) is cloned very recently
[21] from mouse and transcripts coding for this en-
zyme are found in several tissues including pancreas,
spleen, thymus, skin, lung and ovary. In mice, group
IIE is highly expressed in uterus, whereas group IIF
sPLA2 has its highest expression during embryogen-
esis and is also strongly expressed in adult testis [22].
Group V enzyme has been cloned from human and
rat and is strongly expressed in heart tissue [23,24].
This PLA2 has also been detected in P388D1 murine
macrophages [25]. Group X PLA2 has been cloned
from human fetal lung [26] and transcripts coding for
this sPLA2 are found in tissues and cells of the im-
mune system, suggesting a role related to in£amma-
tion and/or immunity.
According to Tisch¢eld [27], many of the reports
describing the expression of group IIA PLA2 in var-
ious cell types and extracellular £uids do require
reevaluation in light of the discovery that some anti-
bodies raised against the group IIA PLA2 appeared
to be cross-reactive with the more recently described
group V PLA2 [25,28]. However, Hara et al. [29] and
Kramer et al. [30] puri¢ed a human non-pancreatic
sPLA2 from rheumatoid arthritis synovial £uid and
unequivocally classi¢ed this enzyme as belonging to
group IIA after N-terminal amino acid sequence
analyses. Therefore, in synovial £uid, most of the
sPLA2 activity is of the type IIA. Green et al. [15]
puri¢ed the circulating PLA2 from the plasma of
patients with sepsis. After amino-terminal sequence
analysis, they concluded that this enzymatic activity
also belonged to the group IIA sPLA2. Likewise,
Schalkwijk et al. [31] incontrovertibly showed the
presence of group IIA PLA2 in the culture medium
of stimulated rat mesangial cells by immunopuri¢ca-
tion and N-terminal sequencing. This PLA2 activity
was secreted into the medium after stimulation of
these cells with the pro-in£ammatory cytokine inter-
leukin-1L.
In a previous study [17], we have shown that sickle
cell patients su¡ering from acute chest syndrome
(ACS) have dramatically elevated levels of phospho-
lipase A2 activity in sera. There was a linear relation
between the high levels of PLA2 activity and the
amount of PLA2 protein as determined in a sand-
wich ELISA system. In addition, we also demon-
strated a direct correlation between levels of sPLA2
in circulation and clinical severity of ACS. The anti-
bodies used in this particular system were monoclo-
nal antibodies, raised against the human group IIA
PLA2. At that time, we concluded from these results
that the high PLA2 levels present in sera from acute
chest syndrome patients belonged to the group IIA
enzyme. However, in light of the above-mentioned
¢ndings, this conclusion requires reevaluation as
well.
We demonstrate in this study by immunopuri¢ca-
tion and N-terminal sequencing, that the PLA2 ac-
tivity present in sera of acute chest syndrome is
mainly, if not solely, of the group IIA type. An iden-
tical classi¢cation was found for the high PLA2 ac-
tivity in sera from trauma victims.
2. Materials and methods
2.1. A⁄nity puri¢cation of PLA2 from plasma and
sera
Monoclonal antibodies against human group IIA
PLA2 were kindly provided by Dr. F.B. Taylor Jr.,
Oklahoma Medical Research Foundation, Oklahoma
City, and were a gift of Dr. E. Hack, Amsterdam.
The antibodies, which are of the IgG 1 class [12],
were puri¢ed and the catching monoclonal antibody
10B2 from the sandwich ELISA system [12,17], was
coupled to CNBr-activated Sepharose 4B (Pharma-
cia, Uppsala, Sweden) according to the instructions
of the supplier.
Nineteen serum samples high in PLA2 activity,
collected from 13 di¡erent trauma patients, were
combined. Similarly, 10 serum samples high in
PLA2 activity of 10 di¡erent sickle cell patients
with acute chest syndrome were pooled. Further-
more, 10 serum samples low in PLA2 activity, col-
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lected from 10 di¡erent trauma patients, were com-
bined and used as negative controls.
Pooled sera were diluted 10 times with AcA bu¡er
(20 mM Tris^HCl bu¡er, pH 7.5, 2 mM EDTA, 1 M
NaCl and 20% (v/v) glycerol), dialyzed twice against
the same bu¡er and applied to the monoclonal anti-
body^Sepharose column with a bed volume of 3 ml.
The column was washed extensively with the same
AcA bu¡er. Enzymatic activity was eluted with 0.1
M glycine^HCl bu¡er, pH 2.5, containing 0.5 M
NaCl (glycine bu¡er, pH 2.5). Fractions were col-
lected, directly neutralized with 1 M Tris^HCl bu¡er,
pH 8.5, and assayed for PLA2 activity. Active frac-
tions were combined, concentrated and desalted with
Centriplus ¢lter devices of Amicon (Millipore, Etten-
Leur, The Netherlands), with a cut-o¡ range of 3000
Da. After solvent exchange (25 mM NH4HCO3,
0.01% SDS), in the same ¢lter devices, the samples
were lyophilized. The dried samples were dissolved in
the Laemmli sample cocktail, heated for 2 min at
100‡C and then loaded on SDS^polyacrylamide
gels. Electrophoresis was carried out at a constant
voltage of 150 V. Protein was transferred from the
gel to a PVDF membrane by a semi-dry blot proce-
dure (1.5 mA/cm2 for 2.5 h). Protein bands on the
blot were stained with 0.1% Coomassie brilliant blue
R-250 and destained in 50% methanol. After exten-
sive washing with distilled water, amino acid se-
quence analyses were performed by the Sequence
Center Utrecht using an Applied Biosystem protein
Sequencer Model 477A.
Immunodetection on blots was performed with
two di¡erent monoclonal antibodies, the catching
antibody 10B2 and the detecting antibody 4A1, and
alkaline phosphatase conjugated goat anti-mouse im-
munoglobulins G as described before [31].
Prestained and non-stained protein markers were
from Bio-Rad, Veenendaal, The Netherlands. Puri-
¢ed recombinant human group IIA sPLA2 was
kindly provided by Dr. P.A. Franken [32], Depart-
ment of Enzymology and Protein Engineering,
Utrecht University, Utrecht, The Netherlands.
2.2. Enzyme assays
The biosynthetic substrate 1-acyl-2-[1-14C]lino-
leoyl-sn-glycero-3-phosphoethanolamine was pre-
pared as previously described [33]. Phospholipase
A2 activity was measured with the radioactive sub-
strate in 0.1 M Tris^HCl bu¡er, pH 8.5, 10 mM
Ca2 and an appropriate amount of enzyme in a
¢nal volume of 200 Wl. Reactions were stopped by
extracting the released radio-labeled fatty acid by a
modi¢ed Dole-extraction procedure [34] and the ra-
dioactivity was determined by liquid scintillation
counting.
3. Results and discussion
Initial puri¢cation using an AcA 54 gel ¢ltration
column indicated that all the PLA2 activity present
in sera of acute chest syndrome patients, eluted at
exactly the same position as the PLA2 activity from
rat liver mitochondria [35] and rat platelets, (results
not shown). Therefore, we concluded that the PLA2
activity in these sera belongs to the 14 kDa group of
enzymes.
In order to further characterize this PLA2 activity,
combined sera of acute chest syndrome patients were
loaded onto an immunoa⁄nity column. Results pre-
sented in Fig. 1 indicate that all PLA2 activity was
bound to the column, whereas the bulk of the pro-
tein ran through. After washing the column with
AcA bu¡er (Fig. 1, arrow A), enzymatic activity
was eluted as a sharp peak with a glycine^HCl bu¡-
er, pH 2.5 (Fig. 1, arrow B). N-terminal amino acid
sequence was determined on this immunopuri¢ed en-
zyme after separation on an SDS^polyacrylamide gel
and transfer to a PVDF membrane (Fig. 2). Band I
from this blot yielded the sequence: Asn-Leu-Val-
Asn-Phe-His-Arg- which is identical to the N-termi-
nal sequence of human group IIA sPLA2 from syno-
vial £uid [29,30,36] as well as to that from human
platelets [30]. The apparent Mr of band I in Fig. 2
seemed to be about 19 kDa; however, this anoma-
lous behavior of this PLA2 in our SDS^PAGE sys-
tem was found earlier for rat liver mitochondrial
group IIA PLA2 and for porcine pancreatic group
IB PLA2 [35]. At the time when we were purifying
the PLA2 activity from acute chest serum, it was not
known whether group V PLA2 would show the same
anomalous mobility as group IB and group IIA
PLA2, or whether it would properly migrate with
an apparent molecular mass of 14 kDa on SDS^
PAGE. In view of this uncertainty, we also tried to
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determine the N-terminal sequence in PVDF mem-
brane pieces at positions II and III in Fig. 2. At
position II, the same sequence was found as in
band I, although obviously with a lower yield. In
band III, besides some other amino acid contami-
nants, group IIA was still found and no indications
were obtained for the presence of group IB, group V
or group X PLA2.
In the next experiments, sera of control patients
and of trauma victims with a high PLA2 activity
were puri¢ed via the same immunoa⁄nity column
chromatography, SDS gel electrophoresis and blot-
ting. Hardly any band could be detected at the posi-
tion of PLA2 in the control sera (lanes 2 and 3, Fig.
3), whereas trauma sera did give a clear band at that
position (lanes 4 and 5, Fig. 3). N-terminal sequenc-
ing of band I (lanes 4 and 5) in Fig. 3, unambigu-
ously revealed the presence of group IIA PLA2 in
sera of trauma victims with high PLA2 activity. Se-
quencing of position II and III of the same lanes in
Fig. 3 gave the same results as obtained in the experi-
ment with sera of acute chest syndrome, i.e. clear
presence of group IIA enzyme at position II and
presence of group IIA at position III, next to some
Fig. 3. PVDF membrane after SDS^PAGE and Western blot-
ting of immunopuri¢ed phospholipase A2 activities from sera of
control patients and trauma victims. Immunopuri¢ed control
sera (15 ml), (lanes 2 and 3) and immunopuri¢ed trauma sera
(9 ml), (lanes 4 and 5). Lane 1, prestained marker of 19 kDa.
Fig. 2. PVDF membrane after SDS^PAGE and Western blot-
ting of immunopuri¢ed phospholipase A2 activities from sera of
acute chest syndrome patients. Lane 1, prestained marker of 19
kDa; lanes 2 and 3, equal amounts of immunopuri¢ed PLA2
activity.
Fig. 1. Immunoa⁄nity chromatography of phospholipase A2 activity from sera of acute chest syndrome patients. Combined diluted
sera solution (120 ml) of ACS patients was applied to the monoclonal antibody column. The column was washed with AcA bu¡er (ar-
row A). Enzymatic activity (b) was eluted with glycine^HCl bu¡er, pH 2.5 (arrow B). Protein was measured at 280 nm (R). Frac-
tions (5.5 ml) were collected and assayed for PLA2 activity.
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other amino acid contaminants. No indications for
the presence of other sPLA2s were found. The same
results were obtained for the PLA2 activity in ascitic
£uids (data not shown), although the starting activity
in this £uid was rather low, making it di⁄cult to
establish if all the PLA2 activity was bound to the
immunoa⁄nity column.
Another problem was the common observation
that the enzymatic activity in the starting sera was
not linear with the amount of sera in the assay. This
makes it impossible to determine the recovery of the
enzymatic activity eluted from the immunoa⁄nity
column. For this reason, it cannot be completely ex-
cluded that some enzymatic activity, belonging to
another PLA2 group, remains on the column after
elution with the glycine^HCl bu¡er, pH 2.5.
Although not very likely, we checked this possibility
by applying 10 ml of trauma sera on the immunoaf-
¢nity column. After extensively washing with AcA
bu¡er, two samples of 200 Wl each were taken from
the top of the immunocolumn. The ¢rst 200-Wl frac-
tion was boiled for 2 min with 100 Wl of the Laemmli
sample cocktail. After centrifugation, this sample
cocktail was transferred to the second 200-Wl sample
of the column material and this material was ex-
tracted in the same way. The total extract was put
on an SDS^polyacrylamide gel and blotted to a
PVDF membrane. Sequencing revealed that on top
of the immunocolumn only group IIA PLA2 was
present (results not shown). Again, no indications
were obtained for the presence of group V or group
X PLA2.
When this study was in progress, a sample of hu-
man group V sPLA2 became available (Dr. W. Cho,
Chicago, USA), which was expressed in Escherichia
coli, refolded and puri¢ed by this group [37]. In our
SDS^PAGE system, this human group V PLA2 ac-
tivity showed the same mobility as the 14-kDa
marker protein, whereas the group IIA enzyme mi-
grated at the same position as the 19-kDa marker
protein (Fig. 4). In this way, we were able to discrim-
inate between group IB and IIA at one hand and
group V PLA2 on the other hand by the di¡erence
in mobility in our SDS^PAGE system. It is now clear
that the group V enzyme, if present in the experi-
ments described in Figs. 2 and 3, should have been
detected in fractions II and/or III. On Western blots,
400 ng of this group V PLA2 enzyme was not recog-
nized by the monoclonal antibodies to human group
IIA enzyme (10B2, the ones that were coupled to the
immunoa⁄nity column used in Figs. 2 and 3), where-
Fig. 5. Western blot analyses of human group IIA and group V
sPLA2s. From left to right: prestained markers (as in Fig. 4),
10, 25, and 100 ng of human group IIA sPLA2, prestained
markers, 100, and 400 ng of human group V sPLA2. The
monoclonal antibody used was 10B2.
Fig. 4. Comparison of mobility of human G IIA and human G
V PLA2 protein in a 15% SDS^polyacrylamide gel. Lane 1, pre-
stained molecular mass markers, from top to bottom: dena-
tured protein between stacking and running gel, 107, 74, 49.3,
36.4, 28.5, and 20.9 kDa, respectively. Lanes 2 and 5, human
group IIA PLA2 (0.2 and 0.5 Wg, respectively). Lanes 3 and 6,
human group V PLA2 (0.2 and 0.5 Wg, respectively). Lane 4,
non-stained molecular mass markers, from top to bottom: 200,
116, 97, 66, 45, 31, 21.5, 14.5, and 6.5 kDa, respectively.
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as 10 ng of human group IIA was easily detected
(Fig. 5). The same results were obtained when the
detecting monoclonal antibody (4A1), recognizing a
di¡erent epitope of the group IIA PLA2 from the
sandwich ELISA system [17], was used (results not
shown). In immune precipitation experiments in
which the immunoa⁄nity column material from
Figs. 2 and 3 was used, more than 95% of the enzy-
matic activity of human group IIA PLA2 could be
precipitated, whereas more than 95% of group V
PLA2 remained in solution (results not shown).
Thus the lack of PLA2 activity in the breakthrough
fractions of the immunoa⁄nity column (Fig. 1) con-
stitutes an additional argument that the PLA2 activ-
ity found in sera or plasma of patients with acute
chest syndrome or trauma is nearly exclusively of
the type IIA.
In conclusion we have unequivocally demonstrated
in this study, that the high PLA2 activities present in
sera of acute chest syndrome patients and in sera of
trauma victims is of the group IIA. This was not
only shown by cross-reactivity with monoclonal anti-
bodies raised against the human group IIA PLA2,
but also by N-terminal amino acid sequence analyses
after puri¢cation. Recently, we have found that in
rat mesangial cells, both group IIA and group V
sPLA2 can be induced by stimulation of these cells
with interleukin-1L [38]. However, the expression of
the latter protein was much lower compared to that
of the former enzyme [38,39]. In addition, the extend
of secretion into the cell medium appeared to be
considerably higher for group IIA than for group
V sPLA2 [38]. From the cDNA for both human
group V [23] and human group X sPLA2 [26] it
was concluded that both enzymes will be synthesized
with a presequence. These presequences are compa-
rable with those found in mammalian group IB and
group IIA PLA2s. However, until now no indications
have been found for the presence of these group V
and/or group X enzymes in circulation in diseases,
such as sepsis, malaria, acute chest syndrome and
other in£ammatory diseases.
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